This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
by Zacks Equity Research
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
by Zacks Equity Research
Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.
Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery
by Zacks Equity Research
Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
by Zacks Equity Research
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study
by Zacks Equity Research
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.
Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
by Zacks Equity Research
Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.
Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%
by Zacks Equity Research
Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
by Zacks Equity Research
Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
by Zacks Equity Research
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
by Zacks Equity Research
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication
by Zacks Equity Research
Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.
CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why
by Zacks Equity Research
Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.
Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
by Zacks Equity Research
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
by Zacks Equity Research
Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
by Zacks Equity Research
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.